Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 662

Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA

Dr Nitin Jain speaks to ecancer at ASH 2018 about the trial looking at the combination of ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL.

He reports that at one year of the combination 61% of patients had undetectable MRD and almost 90% of patients had achieved a complete remission.

Dr Jain explains that the efficacy of the drugs is much higher in combination over separate use, however he does mention that 50% experienced a side effect of neutropenia, although it was manageable.

Related videos

follow us

Breast Cancer CDK 4/6

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation